The U.S. medical foods market size was estimated at USD 6.9 billion in 2025 and is projected to reach USD 10.7 billion by 2033, growing at a CAGR of 5.5% 2026 to 2033. This growth is driven by the rising geriatric population, growing prevalence of chronic diseases, and increasing adoption of disease-specific nutritional formulas.
The growing prevalence of chronic diseases further accelerates demand for disease-specific nutritional interventions. According to the data published by the Centers for Disease Control and Prevention in April 2025, approximately 194 million U.S. adults, which is 76.4%, reported at least one chronic condition, while over 51% had multiple chronic conditions. Among older adults, the burden is even higher, with nearly 93% of individuals aged 65+ having at least one chronic disease in 2023.
Neurological conditions such as Alzheimer’s are particularly significant, with about 7.2 million Americans currently living with the disease, and projections indicating continued growth. This rising disease burden creates sustained demand for medical foods as adjunct therapy in clinical treatment pathways.
The rising incidence of chronic and rare diseases, along with advances in targeted therapies, is driving demand for disease-specific medical foods. These products are increasingly used in the management of conditions such as cancer, gastrointestinal disorders, and metabolic diseases, where tailored nutrition is essential to support treatment outcomes and avoid drug-nutrient interactions. For instance, gastrointestinal patients require easily digestible, tolerance-focused formulas, while oncology patients benefit from high-protein, energy-dense solutions to manage treatment-related complications. Leading companies such as
This product will be delivered within 1-3 business days.
The growing prevalence of chronic diseases further accelerates demand for disease-specific nutritional interventions. According to the data published by the Centers for Disease Control and Prevention in April 2025, approximately 194 million U.S. adults, which is 76.4%, reported at least one chronic condition, while over 51% had multiple chronic conditions. Among older adults, the burden is even higher, with nearly 93% of individuals aged 65+ having at least one chronic disease in 2023.
Neurological conditions such as Alzheimer’s are particularly significant, with about 7.2 million Americans currently living with the disease, and projections indicating continued growth. This rising disease burden creates sustained demand for medical foods as adjunct therapy in clinical treatment pathways.
The rising incidence of chronic and rare diseases, along with advances in targeted therapies, is driving demand for disease-specific medical foods. These products are increasingly used in the management of conditions such as cancer, gastrointestinal disorders, and metabolic diseases, where tailored nutrition is essential to support treatment outcomes and avoid drug-nutrient interactions. For instance, gastrointestinal patients require easily digestible, tolerance-focused formulas, while oncology patients benefit from high-protein, energy-dense solutions to manage treatment-related complications. Leading companies such as
- Abbott Osmolite 1.2 / 1.5 Cal: A fiber-free enteral formula designed for patients with gastrointestinal intolerance, supporting nutrient absorption and tolerance in sensitive patients.
- Danone Milupa Product Range: Foods for Special Medical Purposes (FSMPs) intended for the dietary management of inherited metabolic disorders, supporting growth and nutrient requirements under medical supervision.
- Nestlé BOOST SOOTHE: A clear, high-calorie oral nutritional supplement designed for patients experiencing oral discomfort, taste changes, or mucositis, particularly during cancer treatment. It provides 300 kcal and 10 g of protein per serving, in a soothing, easy-to-drink format, to help maintain weight and nutrition.
U.S. Medical Foods Market Report Segmentation
This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, the analyst has segmented the U.S. medical foods market report based on route of administration, product, application, module, sales channel, and region:Route of Administration Outlook (Revenue, USD Million, 2021-2033)
- Oral
- Enteral
Product Outlook (Revenue, USD Million, 2021-2033)
- Powder
- Pills
- Liquid
- Other
Application Outlook (Revenue, USD Million, 2021-2033)
- Chronic Kidney Disease
- Minimal Hepatic Encephalopathy
- Chemotherapy-Induced Diarrhea
- Pathogen-Related Infections
- Diabetic Neuropathy
- ADHD
- Depression
- Alzheimer's Disease
- Nutritional Deficiency
- Orphan Diseases
- Tyrosinemia
- Eosinophilic Esophagitis
- FPIES
- Phenylketonuria
- MSUD
- Homocystinuria
- Others
- Wound Healing
- Chronic Diarrhea
- Constipation Relief
- Protein Booster
- Dysphagia
- Pain Management
- Parkinson's Disease
- Epilepsy
- Other cancer-related treatments
- Severe Protein Allergy
- Cancer
- Cachexia
- Other
Module Outlook (Revenue, USD Million, 2021-2033)
- Amino Acid Module
- Protein Module
- Vitamin & Mineral Modules
- Fatty Acid-based Modules
- Carbohydrate Modules
- Fiber Modules
- Ketogenic Modules
- Peptide-based Modules
- Hypoallergenic Modules
- Others (Electrolyte Module, etc.)
Sales Channel Outlook (Revenue, USD Million, 2021-2033)
- DTC Sales Channel
- Online Sales
- Retail Sales
- Institutional Sales
- Hospitals
- Others (Long-term Care Facilities, etc.)
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Market Variables, Trends, and Scope
Chapter 4. U.S. Medical Foods Market: Route of Administration Estimates & Trend Analysis
Chapter 5. U.S. Medical Foods Market: Product Estimates & Trend Analysis
Chapter 6. U.S. Medical Foods Market: Application Estimates & Trend Analysis
Chapter 7. U.S. Medical Foods Market: Module Estimates & Trend Analysis
Chapter 8. U.S. Medical Foods Market: Sales Channel Estimates & Trend Analysis
Chapter 9. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
- Danone
- Nestlé
- Abbott
- Targeted Medical Pharma, Inc.
- Fresenius Kabi AG
- Primus Pharmaceuticals, Inc.
- Mead Johnson & Company, LLC (Acquired by Reckitt Benckiser Group PLC)
- Alfasigma USA, Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 90 |
| Published | May 2026 |
| Forecast Period | 2025 - 2033 |
| Estimated Market Value ( USD | $ 6.9 Billion |
| Forecasted Market Value ( USD | $ 10.7 Billion |
| Compound Annual Growth Rate | 5.5% |
| Regions Covered | United States |
| No. of Companies Mentioned | 8 |
